US drug agency approves breakthrough treatment for pancreatic cancer
The US Food and Drug Administration has approved daraxonrasib, a daily pill for pancreatic cancer that nearly doubled average survival in a late-stage trial. The decision offers a significant new treatment option for a cancer that is often diagnosed late, spreads quickly and has the highest death rate among major cancers.
In a 500-patient trial, people taking daraxonrasib lived for an average of 13.2 months, compared with 6.6 months for those receiving chemotherapy. The drug targets mutated KRAS, found in more than 90% of pancreatic tumours; severe side effects affected 44% of treated patients, versus 57.5% on chemotherapy, although rash, diarrhoea, nausea, fatigue and vomiting were common.
- FDA approves a pancreatic cancer pill after strong trial results
- Average survival rose from 6.6 to 13.2 months
- The drug targets a mutation common in pancreatic tumours
Both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Supporters would argue that approval is justified because pancreatic cancer is exceptionally lethal and has long lacked effective options, while the trial shows a substantial survival improvement over chemotherapy. A targeted daily treatment for the KRAS mutation found in most pancreatic tumours could give patients a meaningful additional choice, particularly when the reported rate of severe side effects was lower than with chemotherapy. They would stress that, in a disease often diagnosed too late for cure, timely access to a promising treatment has considerable human value.
The case against
Cautious observers would argue that a striking late-stage result should still be interpreted carefully before the drug becomes widely relied upon. Average survival remained limited, common adverse effects were significant, and the report does not establish how durable the benefit is across different patients, mutation profiles or treatment settings. They would favour close post-approval monitoring, transparent evidence on quality of life and access, and continued research to ensure enthusiasm does not outpace the evidence.